RVMD

Revolution Medicines, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $205.89
52-Week Range: $45.80 – $224.31
Market Cap: $44.29B
P/E (TTM): —
EPS (TTM): -8.87
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 27.58
PEG Ratio: —
Return on Equity: -79.09%
Return on Assets: -30.12%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 11.38
Debt/Equity: 0.46
Total Debt: $1.19B
Free Cash Flow: $-711.61M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $41.54B

RVMD Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$35.38M	$11.58M	$0.00	$0.00
Research & Development	$253.07M	$423.14M	$592.23M	$987.33M
Selling, General & Admin	$40.59M	$75.62M	$97.30M	$195.04M
Operating Expenses	$293.66M	$498.76M	$689.52M	$1.18B
Operating Income	-$258.28M	-$487.19M	-$689.52M	-$1.18B
EBITDA	-$248.62M	-$430.58M	-$589.02M	-$1.09B
Pretax Income	-$249.13M	-$439.89M	-$600.85M	-$1.13B
Income Tax	-$420.00K	-$3.52M	-$753.00K	$0.00
Net Income	-$248.71M	-$436.37M	-$600.09M	-$1.13B
Diluted EPS	-3.08	-3.86	-3.58	-5.95
Diluted Shares	80.63M	113.15M	167.74M	190.13M

RVMD Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$161.41M	$696.15M	$543.06M	$383.75M
Receivables	$4.67M	$1.25M	$0.00	—
Current Assets	$660.18M	$1.88B	$2.33B	$2.08B
Total Assets	$811.93M	$2.06B	$2.56B	$2.35B
Current Liabilities	$61.98M	$143.85M	$163.91M	$290.42M
Total Debt	$64.20M	$87.94M	$135.84M	$158.70M
Total Liabilities	$126.74M	$235.51M	$293.10M	$723.21M
Retained Earnings	-$701.34M	-$1.14B	-$1.74B	-$2.87B
Shareholders' Equity	$685.19M	$1.83B	$2.27B	$1.63B
Working Capital	$598.20M	$1.74B	$2.16B	$1.78B

RVMD Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$224.40M	-$350.57M	-$557.44M	-$897.74M
Capital Expenditure	-$10.82M	-$7.73M	-$10.31M	-$15.99M
Free Cash Flow	-$235.22M	-$358.30M	-$567.74M	-$913.73M
Depreciation & Amortisation	$9.66M	$9.31M	$11.82M	$16.56M
Stock-Based Compensation	$31.20M	$61.77M	$79.20M	$118.39M
Investing Cash Flow	-$24.12M	-$342.60M	-$554.39M	$118.06M
Financing Cash Flow	$301.43M	$1.23B	$959.41M	$621.52M
Net Change in Cash	$52.91M	$536.03M	-$152.42M	-$158.16M

RVMD Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$205.75M	$224.13M	$262.51M	$294.94M	$343.97M	$394.92M
Selling, General & Admin	$35.01M	$40.58M	$52.76M	$66.68M	$101.25M	$110.21M
Operating Expenses	$240.76M	$264.71M	$315.27M	$361.63M	$445.22M	$505.13M
Operating Income	-$240.76M	-$264.71M	-$315.27M	-$361.63M	-$445.22M	-$505.13M
EBITDA	-$237.04M	-$243.12M	-$289.44M	-$348.25M	-$437.08M	-$611.55M
Pretax Income	-$213.42M	-$247.79M	-$305.21M	-$364.89M	-$453.82M	-$644.37M
Net Income	-$213.42M	-$247.79M	-$305.21M	-$364.89M	-$453.82M	-$644.37M
Diluted EPS	-1.13	-1.31	-1.61	-1.86	-2.29	-3.06
Diluted Shares	188.15M	188.58M	189.23M	196.67M	198.10M	210.89M

RVMD Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$333.55M	$402.44M	$217.44M	$383.75M	$440.94M	$815.43M
Current Assets	$2.13B	$2.18B	$1.98B	$2.08B	$1.97B	$4.03B
Total Assets	$2.37B	$2.43B	$2.25B	$2.35B	$2.25B	$4.32B
Current Liabilities	$158.60M	$184.53M	$245.62M	$290.42M	$289.60M	$354.06M
Long-Term Debt	—	—	—	—	—	$487.43M
Total Debt	$134.34M	$132.79M	$158.46M	$158.70M	$156.63M	$641.93M
Total Liabilities	$287.20M	$564.20M	$655.02M	$723.21M	$753.82M	$1.72B
Retained Earnings	-$1.95B	-$2.20B	-$2.50B	-$2.87B	-$3.32B	-$3.97B
Shareholders' Equity	$2.08B	$1.87B	$1.60B	$1.63B	$1.50B	$2.61B
Working Capital	$1.98B	$1.99B	$1.73B	$1.78B	$1.68B	$3.67B

RVMD Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$194.44M	-$221.76M	-$207.31M	-$274.24M	-$354.17M	-$741.48M
Capital Expenditure	-$3.27M	-$7.45M	-$3.35M	-$1.93M	-$1.54M	-$3.82M
Free Cash Flow	-$197.70M	-$229.21M	-$210.66M	-$276.16M	-$355.70M	-$745.31M
Depreciation & Amortisation	$3.72M	$3.80M	$4.34M	$4.70M	$4.54M	$9.04M
Stock-Based Compensation	$25.08M	$28.83M	$30.78M	$33.70M	$87.30M	$154.30M
Investing Cash Flow	-$15.95M	$34.28M	$24.85M	$74.88M	$172.62M	-$1.49B
Financing Cash Flow	$874.00K	$256.58M	-$1.59M	$365.66M	$238.74M	$2.66B
Net Change in Cash	-$209.51M	$69.10M	-$184.05M	$166.30M	$57.19M	$431.69M

Market Snapshot

About

Revolution Medicines, Inc. is a clinical-stage precision oncology company developing targeted therapies for RAS-addicted cancers. The company focuses on creating innovative small molecule drugs that address difficult-to-treat cancers driven by RAS mutations, one of the most common oncogenic drivers. Revolution Medicines utilizes a structure-based drug design platform to advance multiple programs through clinical development.